Vanguard Global Advisers
TERN

Vanguard Global Advisers’s Terns Pharmaceuticals TERN Stock Holding History

Vanguard Global Advisers’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,597
Closed -$1.82M – 3730
2026
Q1 		$1.82M Buy
+34,597
New +$1.42M ﹤0.01% 1252

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Global Advisers's TERN Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 34,597 shares — an estimated $1.82M sold.

Vanguard Global Advisers first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $1.82M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 34,597 Terns Pharmaceuticals shares in Q2 2026, an estimated $1.82M.
  • Vanguard Global Advisers first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Terns Pharmaceuticals position peaked at $1.82M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.